diabetes Type 2 diabetes mellitus
Conditions
Interventions
During the study no change in lifestyle will be advised. Each arm contains 30
patients who will receive for 4 weeks
Control (group1), L-glutamine 0.3-0.5
g/kg/day (group 2), EGCG 3 x 150mg/day or no intervention (group 3) and
L-glutamine/EGCG (group 4). Both L-glutamine and EGCG are produced according
GMP quidel
Sponsors
Medisch Centrum Alkmaar
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with newly diagnosed type 2 diabetes mellitus Ages eligible for study 30 - 80 years old Genders eligible for study both gender postabsorptive glucose two times >7 mmoll/L, BMI
Exclusion criteria
Exclusion criteria: Post absorptive glucose * 15mmol/l Post absorptive glucose * 10 mmol/l and hyperglycemic complaints (polydipsia, polyuria and loss of weight more than 10% in the last month) Creatinine clearance of 3 times the upper level of normal Patients known to suffer from any malignancy, an acute illness, life threatening disease, or chronic inflammatory condition at the start of the study. Use of corticosteroids or other anti-inflammatory medication Preexisting cardiovascular diseases or atherosclerotic diseases. Pregnancy/breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary study parameters: Insulin sensitivity, by using an OGTT | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary study parameters: Other inflammatory parameters (CRP,IL-6, IL-18, TNF-*, leucocyte NFkappaB, IL-4, IL-10). IL-6 en TNF-* na vol bloed LPS stimulatie. Oxidatieve stress parameters(Malondialdehyde, TBARS, 8-iso-prostaglandin F2*). Endothelial dysfunction parameters (VCAM-1, E-selectin, ICAM-1, vWF, cGMP, nitrate/nitrite). Pro-coagulant state (PAI-1, fibrinogen, P-selectin) Body composition (BIA). Weight changes | — |
Countries
Netherlands
Outcome results
None listed